E5564

DRUG2 trials

Sponsors

Eisai Inc.

Conditions

InfectionLeukemiaSepsisSepsis SyndromeSepticemiaShock, Septic

Phase 1

A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

TerminatedNCT00756912

Eisai Inc.Leukemia

Start: 2008-09-30Updated: 2014-07-11

Phase 2

A Safety and Efficacy Study of Intravenous E5564 in Patients With Severe Sepsis

CompletedNCT00046072

Eisai Inc.Infection, Sepsis, Sepsis Syndrome +2

Start: 2001-10-31End: 2005-04-30Target: 300Updated: 2005-12-12